New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareTestagen vs P21

Testagen vs P21

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & Longevity
Testagen
Cognitive EnhancementAnti-Aging & Longevity
P21
Summary
Testagen is a tetrapeptide bioregulator (Lys-Glu-Asp-Gly) developed by Professor Vladimir Khavinson, tissue-specific for the testes. It supports Leydig cell function, normalization of testosterone biosynthesis, and spermatogenic activity. Testagen is used in men's health protocols for age-related testosterone decline, male fertility support, and testicular anti-aging.
P21 is a synthetic peptide derived from CNTF (ciliary neurotrophic factor) that promotes hippocampal neurogenesis, enhances memory and spatial learning, and may reduce amyloid-beta pathology. It is used as a neurogenic and cognitive enhancer with potential anti-Alzheimer's applications.
Half-Life
Short (minutes); sustained gene-regulatory effects
Not well characterized; likely short, but neurogenic effects persist long after administration
Admin Route
SubQ, Oral
SubQ, Intranasal
Research
Typical Dose
10 mg per day
100–500 mcg
Frequency
Daily for 10–30 days
Once daily
Key Benefits
  • Supports endogenous testosterone synthesis via Leydig cell normalization
  • Promotes spermatogenesis and sperm quality
  • Anti-aging effects on testicular tissue
  • May attenuate age-related testosterone decline
  • Mechanistically distinct from TRT — does not suppress HPG axis
  • Useful adjunct to Gonadorelin and Kisspeptin-10 in male hormonal protocols
  • Supports male fertility without exogenous hormone replacement
  • Promotes hippocampal neurogenesis
  • Enhances spatial memory and learning
  • Increases BDNF expression
  • Reduces amyloid-beta plaque formation (animal models)
  • Anti-tau pathology potential
  • Cognitive enhancement without stimulant effects
  • Potential therapeutic for Alzheimer's and cognitive aging
Side Effects
  • Generally well tolerated
  • Mild injection site reactions
  • No significant endocrine disruption reported at standard doses
  • Generally well tolerated in animal studies
  • Limited human clinical data
  • Injection site reactions
  • Potential mild fatigue at initiation
Stacks With